Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0733, simvastatin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| MK0733, simvastatin | DRUG | - |
| Comparator: simvastatin | DRUG | - |
Inclusion Criteria: * Elevated cholesterol level Exclusion Criteria: * Liver disease * Known allergies to study drugs
MK0733, simvastatin is a small molecule being studied for hypercholesterolemia and low HDL cholesterol. It is in Phase 3 clinical development for these metabolic conditions. The drug is investigational and not yet approved.
Organon & Co. (NYSE: OGN) is developing MK0733, simvastatin. The company is conducting Phase 3 clinical trials for the drug in hypercholesterolemia and HDL cholesterol.
MK0733, simvastatin is in Phase 3 clinical development. It is an investigational drug being studied for hypercholesterolemia and low HDL cholesterol. It has not been approved by regulatory authorities.
MK0733, simvastatin has been studied in two completed Phase 3 trials. NCT00092157 enrolled 571 patients with hypercholesterolemia, and NCT00389896 enrolled 150 patients with type 2 diabetes to evaluate effects on HDL cholesterol. Both trials are completed.
Yes, MK0733, simvastatin is the same as simvastatin. The drug is referred to by both names in clinical trials. It is being developed by Organon & Co. for hypercholesterolemia and HDL cholesterol.